Advertisement

Drugs

, Volume 39, Issue 3, pp 394–398 | Cite as

Self-Administration in the Pharmacological Treatment of Impotence

  • Francois Bénard
  • Tom F. Lue
Practical Therapeutic

Summary

Recent innovative research into the physiology and pharmacology of erection and the introduction of intracavernous injection of vasoactive agents have revolutionised our approach to the diagnosis and treatment of impotence. A thorough understanding of the rationale, indications, precautions and potential complications of intracavernous self-injection is essential for successful management.

The commonly used drugs for injection are papaverine, either alone or in combination with phentolamine, and alprostadil (prostaglandin E1). The major adverse effects include priapism, prolonged erection, and fibrosis of the erectile tissue. With the proper technique and appropriate dosage, this is a safe, minimally invasive, and highly effective treatment.

Keywords

Impotence Papaverine Phentolamine Priapism Alprostadil 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Aboseif SR, Breza J, Bosch RJLH, Bernard F, Stief CG, et al. Local and systemic effects of chronic intracavernous injection of papaverine, prostaglandin E1, and saline in primates. Journal of Urology 142: 403–408, 1989PubMedGoogle Scholar
  2. Brindley GS. Cavernosal alpha-blockade: a new technique for investigating and treating erectile impotence. British Journal of Psychiatry 143: 332–337, 1983PubMedCrossRefGoogle Scholar
  3. Ishii N, Watanabe H, Irisawa C, Kikuchi Y, Kawamura S, et al. Studies on male sexual impotence. Report 18: therapeutic trial with prostaglandin E1 for organic impotence. Japanese Journal of Urology 77: 954–962, 1986PubMedGoogle Scholar
  4. Juenemann KP, Lue TF, Fournier Jr GR, Tanagho EA. Hemodynamics of papaverine-and phentolamine-induced penile erection. Journal of Urology 136: 158–161, 1986PubMedGoogle Scholar
  5. Keogh EJ, Watters GR, Earle CM, Carati CJ, Wisniewski ZS, et al. Treatment of impotence by intrapenile injections. A comparison of papaverine and phentolamine: a double-blind, crossover trial. Journal of Urology 142: 726–728, 1989Google Scholar
  6. Robinson LQ, Stephenson TP. Self injection treatment for impotence. British Medical Journal 299: 1568, 1989PubMedCrossRefGoogle Scholar
  7. Sidi AA, Cameron JS, Duffy LM, Lange P. Intracavernous drug induced erection in the management of male erectile dysfunction: experience with 100 patients. Journal of Urology 135: 704–706, 1986PubMedGoogle Scholar
  8. Sidi AA, Cameron JS, Duffy LM, Lange P. Patient acceptance of and satisfaction with vasoactive intracavernous pharmacotherapy for impotence. Journal of Urology 140: 293–294, 1988PubMedGoogle Scholar
  9. Stackl W, Hasun R, Marberger M. Intracavernous injection of prostaglandin E1 in impotent men. Journal of Urology 140: 66–68, 1988PubMedGoogle Scholar
  10. Virag R. Intracavernous injection of papaverine for erectile failure. Correspondence. Lancet 2: 938, 1982CrossRefGoogle Scholar
  11. Zorgniotti AW, Lefleur RS. Auto-injection of corpus cavernosum with a vasoactive drug combination for vasculogenic impotence. Journal of Urology 133: 39–41, 1985PubMedGoogle Scholar

Copyright information

© ADIS Press Limited 1990

Authors and Affiliations

  • Francois Bénard
    • 1
  • Tom F. Lue
    • 1
  1. 1.Department of Urology, U-518University of California School of MedicineSan FranciscoUSA

Personalised recommendations